Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- major depressive episode(s)
- episode(s) of manic or mixed episodes
- episode(s) of hypomania
- inflated self-esteem or grandiosity
- decreased need for sleep
- more talkative than usual, or feels pressure to keep talking
- flight of ideas, or subjective experience that thoughts are racing
- distractibility
- increase in goal-directed activity or psychomotor agitation
- excessive involvement in pleasurable activities that have a high potential for adverse consequences
- functional impairment
- no substance misuse
- no underlying medical cause
- not due to somatic antidepressant treatment or other prescribed medication
Risk factors
- family history of bipolar disorder
- onset of mood disorder prior to 20 years of age
- stressful life events
- previous history of depression
- lifetime history of a substance misuse disorder
- presence of an anxiety disorder
- obesity
- cardiovascular disease
Diagnostic investigations
1st investigations to order
- Primary Care Evaluation of Mental Disorders (PRIME-MD)
- Patient Health Questionnaire (PHQ-9)
- Mood Disorder Questionnaire (MDQ)
- Composite International Diagnostic Interview (CIDI)
- Bipolarity Index
- Young Mania Rating Scale (YMRS)
- FBC
- thyroid function tests
- serum vitamin D
- toxicology screen
Treatment algorithm
Contributors
Authors
Assistant Professor of Psychiatry
University of Texas Health Science Center
Houston
TX
Disclosures
SS has received intravenous citalopram for research from Lundbeck UK and participated as a speaker organised by Global Medical Education. SS has third-party indirect share in the form of convertible note in Flow MedTech, Inc (a medical device start-up company).
Dr Sudhakar Selvaraj would like to gratefully acknowledge Dr Prashant Gajwani and Dr David J. Muzina, previous contributors to this topic. PG has served on the speakers' bureau for Merck and Sunovion. DJM is an author of a number of references cited in this topic. DJM has previously received honoraria for research support from Repligen Co. He has also previously received honoraria as a speaker and/or advisor from AstraZeneca, Pfizer, BMS, Wyeth, Sepracor, and GSK. DJM is a full-time employee of Medco.
Peer reviewers
Head
Mood Disorders Psychopharmacology Unit
University Health Network
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Ontario
Canada
Disclosures
RM has received research funds from Stanley Medical Research Institute and National Alliance for Research on Schizophrenia and Depression (NARSAD). RM is on the advisory boards for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. RM is on the speakers' bureau for Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck, Biovail, and Wyeth. RM has received research grants from Eli Lilly, Janssen-Ortho, and Shire.
Professor of Psychological Medicine
University of Newcastle
Honorary Professor
Psychological Treatments Research
Institute of Psychiatry
London
University Department of Psychiatry
Royal Victoria Infirmary
Newcastle upon Tyne
UK
Disclosures
JS has received remuneration for attending advisory boards for AstraZeneca, BSM-Otsuka, Eli Lilly, GSK, and Sanofi-Aventis.
Use of this content is subject to our disclaimer